World Health Organization Sounds Warning Over Severe Shortage of Weight-Loss Jabs
Under one in 10 individuals eligible to benefit from weight-loss injections like Wegovy are able to get them, states the global health agency as it issues its initial advice on the therapies.
With more than one billion individuals worldwide now obese, it is urging increased and just availability to these injectable treatments.
According to projections, more than two billion could be living with obesity by 2030 if no action is taken.
"Our new guidance affirms that obesity is a lifelong illness that can be managed with comprehensive and continuous care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key hurdles to universal access to the treatments that can assist patients in reducing considerable weight, says the agency.
Skinny Jab Scarcity
Even in the current most optimistic scenario, the supply of these medications might only reach around 100 million people – under 10% of eligible patients, according to the health organization.
The advice calls on nations and manufacturers to expand availability, through strategies including licensing agreements.
Exclusive production rights on the active ingredient – the core component of a leading brand – is set to lapse in a number of nations in 2026.
How Weight-Loss Drugs Work
The injections mimick a body's own hormone to slow digestion, curb appetite and increase satiety so individuals eat less.
Patients commonly see weight reduction within a few weeks of starting on the once-weekly jabs.
Research indicates people may regain a significant portion within a year of discontinuing the drug, as their normal food cravings resume.
To be overweight or obese raises your risk for developing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity impacts people in every country and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.
